Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of “Buy” by Brokerages
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has earned a consensus rating of “Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has earned a consensus rating of “Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is […]
